Literature DB >> 19729658

Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a.

Barry Fine1, Cindy Hodakoski, Susan Koujak, Tao Su, Lao H Saal, Matthew Maurer, Benjamin Hopkins, Megan Keniry, Maria Luisa Sulis, Sarah Mense, Hanina Hibshoosh, Ramon Parsons.   

Abstract

PTEN (phosphatase and tensin homolog on chromosome 10) is a tumor suppressor whose cellular regulation remains incompletely understood. We identified phosphatidylinositol 3,4,5-trisphosphate RAC exchanger 2a (P-REX2a) as a PTEN-interacting protein. P-REX2a mRNA was more abundant in human cancer cells and significantly increased in tumors with wild-type PTEN that expressed an activated mutant of PIK3CA encoding the p110 subunit of phosphoinositide 3-kinase subunit alpha (PI3Kalpha). P-REX2a inhibited PTEN lipid phosphatase activity and stimulated the PI3K pathway only in the presence of PTEN. P-REX2a stimulated cell growth and cooperated with a PIK3CA mutant to promote growth factor-independent proliferation and transformation. Depletion of P-REX2a reduced amounts of phosphorylated AKT and growth in human cell lines with intact PTEN. Thus, P-REX2a is a component of the PI3K pathway that can antagonize PTEN in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729658      PMCID: PMC2936784          DOI: 10.1126/science.1173569

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  23 in total

1.  P-Rex1, a PtdIns(3,4,5)P3- and Gbetagamma-regulated guanine-nucleotide exchange factor for Rac.

Authors:  Heidi C E Welch; W John Coadwell; Christian D Ellson; G John Ferguson; Simon R Andrews; Hediye Erdjument-Bromage; Paul Tempst; Phillip T Hawkins; Len R Stephens
Journal:  Cell       Date:  2002-03-22       Impact factor: 41.582

2.  P-REX2, a novel PI-3-kinase sensitive Rac exchange factor.

Authors:  Hans Rosenfeldt; José Vázquez-Prado; J Silvio Gutkind
Journal:  FEBS Lett       Date:  2004-08-13       Impact factor: 4.124

3.  P-Rex2, a new guanine-nucleotide exchange factor for Rac.

Authors:  Sarah Donald; Kirsti Hill; Charlotte Lecureuil; Romain Barnouin; Sonja Krugmann; W John Coadwell; Simon R Andrews; Simon A Walker; Phillip T Hawkins; Len R Stephens; Heidi C E Welch
Journal:  FEBS Lett       Date:  2004-08-13       Impact factor: 4.124

4.  Genetic alterations during colorectal-tumor development.

Authors:  B Vogelstein; E R Fearon; S R Hamilton; S E Kern; A C Preisinger; M Leppert; Y Nakamura; R White; A M Smits; J L Bos
Journal:  N Engl J Med       Date:  1988-09-01       Impact factor: 91.245

5.  Interfacial kinetic analysis of the tumour suppressor phosphatase, PTEN: evidence for activation by anionic phospholipids.

Authors:  George McConnachie; Ian Pass; Steven M Walker; C Peter Downes
Journal:  Biochem J       Date:  2003-05-01       Impact factor: 3.857

6.  PTEN associates with the vault particles in HeLa cells.

Authors:  Zhenbao Yu; Nasser Fotouhi-Ardakani; Liangtang Wu; Meryem Maoui; Shenglong Wang; Denis Banville; Shi-Hsiang Shen
Journal:  J Biol Chem       Date:  2002-08-11       Impact factor: 5.157

Review 7.  PTEN function: how normal cells control it and tumour cells lose it.

Authors:  Nick R Leslie; C Peter Downes
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

Review 8.  PTEN: one gene, many syndromes.

Authors:  Charis Eng
Journal:  Hum Mutat       Date:  2003-09       Impact factor: 4.878

Review 9.  Genetic alterations in breast cancer.

Authors:  I Bièche; R Lidereau
Journal:  Genes Chromosomes Cancer       Date:  1995-12       Impact factor: 5.006

10.  Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis.

Authors:  J Qin; Y Xie; B Wang; M Hoshino; D W Wolff; J Zhao; M A Scofield; F J Dowd; M-F Lin; Y Tu
Journal:  Oncogene       Date:  2009-03-23       Impact factor: 9.867

View more
  109 in total

Review 1.  Molecular pathways: intercellular PTEN and the potential of PTEN restoration therapy.

Authors:  Benjamin D Hopkins; Ramon E Parsons
Journal:  Clin Cancer Res       Date:  2014-11-01       Impact factor: 12.531

2.  Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinoma.

Authors:  Chia-Hung Yen; Yao-Cheng Lu; Chung-Hsien Li; Cheng-Ming Lee; Chia-Yen Chen; Ming-Yuan Cheng; Shiu-Feng Huang; Kuen-Feng Chen; Ann-Lii Cheng; Li-Ying Liao; Yan-Hwa Wu Lee; Yi-Ming Arthur Chen
Journal:  Mol Med       Date:  2012-03-30       Impact factor: 6.354

3.  Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo.

Authors:  Haijun Zhang; Di Chen; Jonathan Ringler; Wei Chen; Qiuzhi Cindy Cui; Stephen P Ethier; Q Ping Dou; Guojun Wu
Journal:  Cancer Res       Date:  2010-04-27       Impact factor: 12.701

4.  Therapeutic targeting of cancers with loss of PTEN function.

Authors:  Lloye M Dillon; Todd W Miller
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

Review 5.  PTEN function: the long and the short of it.

Authors:  Benjamin D Hopkins; Cindy Hodakoski; Douglas Barrows; Sarah M Mense; Ramon E Parsons
Journal:  Trends Biochem Sci       Date:  2014-03-18       Impact factor: 13.807

6.  PtdIns(3,4,5)P3-dependent Rac Exchanger 1 (PREX1) Rac-Guanine Nucleotide Exchange Factor (GEF) Activity Promotes Breast Cancer Cell Proliferation and Tumor Growth via Activation of Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Signaling.

Authors:  Heng-Jia Liu; Lisa M Ooms; Nuthasuda Srijakotre; Joey Man; Jessica Vieusseux; JoAnne E Waters; Yue Feng; Charles G Bailey; John E J Rasko; John T Price; Christina A Mitchell
Journal:  J Biol Chem       Date:  2016-06-29       Impact factor: 5.157

7.  PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.

Authors:  Hiromichi Ebi; Carlotta Costa; Anthony C Faber; Madhuri Nishtala; Hiroshi Kotani; Dejan Juric; Patricia Della Pelle; Youngchul Song; Seiji Yano; Mari Mino-Kenudson; Cyril H Benes; Jeffrey A Engelman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-10       Impact factor: 11.205

8.  Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.

Authors:  Omar Abdel-Wahab; Virginia M Klimek; Alisa A Gaskell; Agnes Viale; Donavan Cheng; Eunhee Kim; Raajit Rampal; Mark Bluth; James J Harding; Margaret K Callahan; Taha Merghoub; Michael F Berger; David B Solit; Neal Rosen; Ross L Levine; Paul B Chapman
Journal:  Cancer Discov       Date:  2014-03-03       Impact factor: 39.397

Review 9.  Regulation and modulation of PTEN activity.

Authors:  Elahe Naderali; Amir Afshin Khaki; Jafar Soleymani Rad; Alireza Ali-Hemmati; Mohammad Rahmati; Hojjatollah Nozad Charoudeh
Journal:  Mol Biol Rep       Date:  2018-08-25       Impact factor: 2.316

10.  Stoichiometric quantification of Akt phosphorylation using LC-MS/MS.

Authors:  Abdelmadjid Atrih; Dan Turnock; Grant Sellar; Alastair Thompson; Giora Feuerstein; Michael A J Ferguson; Jeffrey T-J Huang
Journal:  J Proteome Res       Date:  2010-02-05       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.